Adrenoleukodystrophy

SwanBio raises $56m for rare neurological disease gene therapy

SwanBio Therapeutics has raised $56 million in a second-round financing that will be used to advance its lead gene therapy candidate for adrenomyeloneuropathy (AMN) into clinical testing later this year. The Series B takes the total raised by the Philadelphia-based biotech to $133 million and is earmarked for a phase 1/2 trial of the gene …

SwanBio raises $56m for rare neurological disease gene therapy Read More »

A Complex Chromosomal Abberation Called Adrenoleukodystrophy

The global Adrenoleukodystrophy market size for the forecast period 2020-30, which was estimated to be USD 922.43 million in the 7MM in 2017 is driven by key pharma players such as Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, and others are proactively focusing on advancing ALD pipeline, increasing prevalence, and increased R&D in the …

A Complex Chromosomal Abberation Called Adrenoleukodystrophy Read More »